Manila Times Business
Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution
Ready-to-use romidepsin formulation; offers a more convenient alternative to lyophilized powder requiring reconstitutionCompetitive Generic Therapy approval provides 180 days of market exclusivity and further expands Amneal’s differentiated injectables portfolio BRIDGEWATER, N.J., June 04, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. ("Amneal” or the "Company”) (Nasdaq: AMRX) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s romidepsin injection
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Trusted by the Majority of Top 30 U.S. Accounting Firms, Caseware Launches Verity Agentic Pioneer Program
Just now
IperionX Titan DFS Confirms High-Return U.S. Rare Earths and Critical Minerals Project
Just now
Weight Watchers to Increase Access to Comprehensive Weight Loss Options for Patients Nationwide through LillyDirect
Just now
Innovation Labs by Identity Digital Submits DNS-Anchored Durable Identity Proposal for AI Agents to the IETF
Just now